Suche senden
Hochladen
Sorrento Investor Presentation
•
1 gefällt mir
•
1,073 views
RedChip Companies, Inc.
Folgen
Sorrento Investor Presentation
Weniger lesen
Mehr lesen
Investorbeziehungen
Melden
Teilen
Melden
Teilen
1 von 35
Jetzt herunterladen
Downloaden Sie, um offline zu lesen
Empfohlen
Corporate Presentation - July 2013
Corporate Presentation - July 2013
OpexaTherapeutics
Kiromic Presentation 2020
Kiromic Presentation 2020
RedChip Companies, Inc.
doing business in the us (pharma-medical device)
doing business in the us (pharma-medical device)
Jean-Xtophe Ordonneau
Asco pfizer analyst call slides final
Asco pfizer analyst call slides final
pfizer_ir
Cgix vc oct2013
Cgix vc oct2013
RedChip Companies, Inc.
MMJ Investor Deck
MMJ Investor Deck
MMJCanada
Impax Laboratories Credit Suisse 2012 Healthcare Conference Presentation
Impax Laboratories Credit Suisse 2012 Healthcare Conference Presentation
ImpaxLaboratories
Can fite presentation-November 2019
Can fite presentation-November 2019
RedChip Companies, Inc.
Weitere ähnliche Inhalte
Was ist angesagt?
Opexa therapeutics corporate presentation december
Opexa therapeutics corporate presentation december
OpexaTherapeutics
Astrazeneca Full year and_q4_2016_results_presentation
Astrazeneca Full year and_q4_2016_results_presentation
The ScientifiK
Opexa therapeutics corporate presentation november 21
Opexa therapeutics corporate presentation november 21
OpexaTherapeutics
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Michael Swit
One Decade Later - Energy Predictions of the EIA
One Decade Later - Energy Predictions of the EIA
JeremyMcCreaCFA
Biotech 2008 Evolution Of Capital Session Slides For Walter Mel Anne Gary Chris
Biotech 2008 Evolution Of Capital Session Slides For Walter Mel Anne Gary Chris
cschnittker
Was ist angesagt?
(6)
Opexa therapeutics corporate presentation december
Opexa therapeutics corporate presentation december
Astrazeneca Full year and_q4_2016_results_presentation
Astrazeneca Full year and_q4_2016_results_presentation
Opexa therapeutics corporate presentation november 21
Opexa therapeutics corporate presentation november 21
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
Generic Drug Labeling Proposed Rule: The Generic Drug Industry Perspective
One Decade Later - Energy Predictions of the EIA
One Decade Later - Energy Predictions of the EIA
Biotech 2008 Evolution Of Capital Session Slides For Walter Mel Anne Gary Chris
Biotech 2008 Evolution Of Capital Session Slides For Walter Mel Anne Gary Chris
Ähnlich wie Sorrento Investor Presentation
Sorrento Investor Presentation
Sorrento Investor Presentation
RedChip Companies, Inc.
Prescient Therapeutics Investor Presentation
Prescient Therapeutics Investor Presentation
Corey Hulls
Genetic Technologies Investor Presentation July 2022
Genetic Technologies Investor Presentation July 2022
RedChip Companies, Inc.
Can-Fite BioPharma Presentation October 2019
Can-Fite BioPharma Presentation October 2019
RedChip Companies, Inc.
Annual Shareholder Meeting 2013
Annual Shareholder Meeting 2013
Cytori Therapeutics, Inc.
Tetra Bio Pharma 2 Page Fact Sheet- Q2 2018
Tetra Bio Pharma 2 Page Fact Sheet- Q2 2018
MomentumPR
Can-Fite BioPharma - Investor Presentation December 2020
Can-Fite BioPharma - Investor Presentation December 2020
RedChip Companies, Inc.
GrowthStalk Holdings.pdf
GrowthStalk Holdings.pdf
StevenEarley1
Can-Fite BioPharma - Investor Presentation Sept 2020
Can-Fite BioPharma - Investor Presentation Sept 2020
RedChip Companies, Inc.
TapImmune Investor Presentation
TapImmune Investor Presentation
RedChip Companies, Inc.
Agility health investor presentation - investor tab 07.18.16
Agility health investor presentation - investor tab 07.18.16
AgilityHealth
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
Cardinal_Health
Tap Immune Investor Presentation
Tap Immune Investor Presentation
RedChip Companies, Inc.
Idxg Corporate Presentation Global Online Growth Conference - Oct 2016
Idxg Corporate Presentation Global Online Growth Conference - Oct 2016
RedChip Companies, Inc.
Stigma Pharmaceutical
Stigma Pharmaceutical
Eric Liboiron
UBS Conference_May 23_2016_FINAL-update161206_tcm2252_153425
UBS Conference_May 23_2016_FINAL-update161206_tcm2252_153425
Udit Batra
Q3 fy18 earnings deck final
Q3 fy18 earnings deck final
Cardinal_Health
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. Presentation
RedChip Companies, Inc.
Investor Present 04202017
Investor Present 04202017
RedChip Companies, Inc.
Critical Success Factors for a Medical Device Company
Critical Success Factors for a Medical Device Company
Dickson Consulting
Ähnlich wie Sorrento Investor Presentation
(20)
Sorrento Investor Presentation
Sorrento Investor Presentation
Prescient Therapeutics Investor Presentation
Prescient Therapeutics Investor Presentation
Genetic Technologies Investor Presentation July 2022
Genetic Technologies Investor Presentation July 2022
Can-Fite BioPharma Presentation October 2019
Can-Fite BioPharma Presentation October 2019
Annual Shareholder Meeting 2013
Annual Shareholder Meeting 2013
Tetra Bio Pharma 2 Page Fact Sheet- Q2 2018
Tetra Bio Pharma 2 Page Fact Sheet- Q2 2018
Can-Fite BioPharma - Investor Presentation December 2020
Can-Fite BioPharma - Investor Presentation December 2020
GrowthStalk Holdings.pdf
GrowthStalk Holdings.pdf
Can-Fite BioPharma - Investor Presentation Sept 2020
Can-Fite BioPharma - Investor Presentation Sept 2020
TapImmune Investor Presentation
TapImmune Investor Presentation
Agility health investor presentation - investor tab 07.18.16
Agility health investor presentation - investor tab 07.18.16
Dublin day deck 6.1.17 final (1)
Dublin day deck 6.1.17 final (1)
Tap Immune Investor Presentation
Tap Immune Investor Presentation
Idxg Corporate Presentation Global Online Growth Conference - Oct 2016
Idxg Corporate Presentation Global Online Growth Conference - Oct 2016
Stigma Pharmaceutical
Stigma Pharmaceutical
UBS Conference_May 23_2016_FINAL-update161206_tcm2252_153425
UBS Conference_May 23_2016_FINAL-update161206_tcm2252_153425
Q3 fy18 earnings deck final
Q3 fy18 earnings deck final
Advanced Medical Isotope Corp. Presentation
Advanced Medical Isotope Corp. Presentation
Investor Present 04202017
Investor Present 04202017
Critical Success Factors for a Medical Device Company
Critical Success Factors for a Medical Device Company
Mehr von RedChip Companies, Inc.
ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023
RedChip Companies, Inc.
Docola Presentation
Docola Presentation
RedChip Companies, Inc.
INNO Holdings Presentation
INNO Holdings Presentation
RedChip Companies, Inc.
EBI IR Presentation Sep 2023
EBI IR Presentation Sep 2023
RedChip Companies, Inc.
ASPI Investor Deck Oct 2023
ASPI Investor Deck Oct 2023
RedChip Companies, Inc.
MDNA Investor Presentation May 2023
MDNA Investor Presentation May 2023
RedChip Companies, Inc.
DGLY Corporate Investor Relations Deck Oct 2023
DGLY Corporate Investor Relations Deck Oct 2023
RedChip Companies, Inc.
Lantern Pharma Investor Presentation Oct 2023
Lantern Pharma Investor Presentation Oct 2023
RedChip Companies, Inc.
Sharps Investor Deck Oct 2023
Sharps Investor Deck Oct 2023
RedChip Companies, Inc.
Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) Presentation
RedChip Companies, Inc.
1847 Holdings Corporate Presentation 1847 Holdings March 2023
1847 Holdings Corporate Presentation 1847 Holdings March 2023
RedChip Companies, Inc.
Sharps Investor Presentation October 2023
Sharps Investor Presentation October 2023
RedChip Companies, Inc.
SPI Investor Deck October 2023
SPI Investor Deck October 2023
RedChip Companies, Inc.
BFRG Investor Deck September_v2
BFRG Investor Deck September_v2
RedChip Companies, Inc.
BFRG Investor Deck September
BFRG Investor Deck September
RedChip Companies, Inc.
BioVie Presentation September 2023
BioVie Presentation September 2023
RedChip Companies, Inc.
Lantern Pharma September 8, 2023
Lantern Pharma September 8, 2023
RedChip Companies, Inc.
GENE Investor Presentation Genetic Technologies August 2023
GENE Investor Presentation Genetic Technologies August 2023
RedChip Companies, Inc.
Splash Beverage Investor Presentation June 2023
Splash Beverage Investor Presentation June 2023
RedChip Companies, Inc.
SEBV Presentation
SEBV Presentation
RedChip Companies, Inc.
Mehr von RedChip Companies, Inc.
(20)
ZOM Investor Presentations Oct 2023
ZOM Investor Presentations Oct 2023
Docola Presentation
Docola Presentation
INNO Holdings Presentation
INNO Holdings Presentation
EBI IR Presentation Sep 2023
EBI IR Presentation Sep 2023
ASPI Investor Deck Oct 2023
ASPI Investor Deck Oct 2023
MDNA Investor Presentation May 2023
MDNA Investor Presentation May 2023
DGLY Corporate Investor Relations Deck Oct 2023
DGLY Corporate Investor Relations Deck Oct 2023
Lantern Pharma Investor Presentation Oct 2023
Lantern Pharma Investor Presentation Oct 2023
Sharps Investor Deck Oct 2023
Sharps Investor Deck Oct 2023
Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) Presentation
1847 Holdings Corporate Presentation 1847 Holdings March 2023
1847 Holdings Corporate Presentation 1847 Holdings March 2023
Sharps Investor Presentation October 2023
Sharps Investor Presentation October 2023
SPI Investor Deck October 2023
SPI Investor Deck October 2023
BFRG Investor Deck September_v2
BFRG Investor Deck September_v2
BFRG Investor Deck September
BFRG Investor Deck September
BioVie Presentation September 2023
BioVie Presentation September 2023
Lantern Pharma September 8, 2023
Lantern Pharma September 8, 2023
GENE Investor Presentation Genetic Technologies August 2023
GENE Investor Presentation Genetic Technologies August 2023
Splash Beverage Investor Presentation June 2023
Splash Beverage Investor Presentation June 2023
SEBV Presentation
SEBV Presentation
Kürzlich hochgeladen
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
Michael Claudio
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop AG
Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop AG
Terna Capital Markets Day 2024 Presentation
Terna Capital Markets Day 2024 Presentation
Terna SpA
Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024
nicola_mining
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
nicola_mining
Kürzlich hochgeladen
(7)
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
WWW.SOFTSOP.COM PITCH DECK PRESENTATION.PDF
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Osisko Gold Royalties Ltd - Corporate Presentation, March 2024
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Company Presentation | 03/24
Deutsche EuroShop | Preliminary Results FY 2023
Deutsche EuroShop | Preliminary Results FY 2023
Terna Capital Markets Day 2024 Presentation
Terna Capital Markets Day 2024 Presentation
Nicola Mining Inc. Corporate Presentation March 2024
Nicola Mining Inc. Corporate Presentation March 2024
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Advancing Discovery New Craigmont Project’s High-grade Copper Potential
Sorrento Investor Presentation
1.
Corporate Investor Presentation March
2018 V030918
2.
Disclaimer Certain statements contained
in this presentation or in other documents of Sorrento Therapeutics, Inc. (the “Company”) and of any of its affiliates, along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate," “projected” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Statements regarding future action, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or approval and commercial launch and sales results (if any) of the Company’s formulations and products and regulatory filings related to the same, and receipt by the Company of milestone and royalty payments may differ from those set forth in the forward-looking statements. Peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achieved, if at all, or that such market size estimates will prove accurate. The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's Form 10-K, 10-Q and 8-K reports. In presenting this material or responding to inquiries in connection with a presentation, management may refer to results, projections or performance measures that are not prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) as reported in the Company’s SEC filings. These results, projections or performance measures are non-GAAP measures and are not intended to replace or as a substitute for results measured under GAAP, but rather as supplement to the GAAP reported results. Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its Securities and Exchange Commission (“SEC”) filings on Forms 10-K, 10-Q and 8-K, and investors are advised to consult the Company’s filings for a more complete listing of risk factors, contingencies and uncertainties effecting the Company and its business and financial performance. Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc. ZTlido™ and G-MAB™ are trademarks owned by Scilex Pharmaceuticals, Inc. and Sorrento, respectively. Seprehvir®, is a registered trademark of Virttu Biologics Limited, a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc. All other trademarks are the property of their respective owners. 2 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
3.
Recent Milestone: 02/28/18
US FDA APPROVAL 3 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
4.
Immuno-Oncology and Non-Opioid
Pain Management 4 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
5.
CAR-T Immune Therapies
for Hematological Malignancies › CAR-T cell therapies are the “game-changer” therapeutic modalities against hematological malignancies … › Treatment pricing (per patient) in the $350K to $500K range. › Anti-CD19 CAR-T Cell Therapies: • Kymriah™ (Novartis): ALL in children and young adults • Yescarta™ (Kite/Gilead): Certain B cell lymphomas • $$$ Gilead acquired Kite for $11.9B (2017) • $$$ Celgene acquired Juno for $9B cash (2018) Global Data Reports, Company websites, Stock Market Historical data 5 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
6.
Future Outlook on
CAR-T Therapies (Competition) CD19 BCMA CD38 SORRENTO is the future Celularity, Cellectis/Pfizer SRNE Allogeneic CAR-T Autologous CAR-T BlueBird, Juno, Kite, GenScript SRNE 6 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
7.
Outlook on SRNE
Next-Generation CAR-T Technology 77 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved CAR-T (Current) • Autologous • Viral Transduction CAR-T (2.0) • Autologous • Non-viral (KOKI*) CAR-T (3.0) • Allogeneic • Non-viral (KOKI*) * KOKI = “Knock-Out/Knock-In” non-viral technology proprietary to Sorrento therapeutics for non viral CAR-T manufacturing
8.
Industry-Leading CD38 CAR-T
Program 8 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
9.
Hematological Malignancies in
the US 9 82K ALL Patients (US) 2024 market forecast: $1B CD19: Novartis (Kymriah™) © 2018 Sorrento Therapeutics, Inc. All Rights Reserved * Global Data reports 2016 (market forecast) and NIH Cancer Institute Statistical Facts (Disease incidence and prevalence) 662K NHL Patients (US) 2024 market forecast: $5.4B CD19: Kite (Yescarta™) 120K MM Patients (US) 2023 market forecast: $22.6B CD38: Janssen/GenMab (Darzalex®) CD38: Sorrento (CD38 CAR-T) BCMA: Bluebird Bio (bb2121 for BCMA CAR-T)
10.
CD38 CAR-T for
Multiple Myeloma › CD38 is a Validated, High Priority Target for MM Immunotherapies: • Darzalex® mAb (Janssen). License from Genmab. • $$$ GenMab Market cap: $12.65B (March 2018) • $$$ Darzalex expected 2022 sales of $5.8B in MM Global Data Reports, Company websites, Stock Market Historical data 10 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
11.
Sorrento CD38 CAR-T
Program: A Very Big Opportunity › Addressing Multiple Myeloma indication => $22 B market opportunity › Targeting validated, high value CD38 target (Darzalex®; anti-CD38 mAb approved for MM treatment) › Proven CAR-T cell therapy modality for hematologic malignancies (Kymriah™ & Yescarta™ for CD19 CAR-T) › Development overseen by a seasoned clinical team, with success track record in MM › cGMP facilities and manufacturing ready for clinical trials › Most advanced CD38 CAR-T program in the industry 11 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
12.
Sorrento – Most
Advanced CD38 CAR-T Program in Development › CAR based on fully human anti-CD38 antibody o Different binding site than Darzalex® on CD38 o Different kinetic binding profile o Preference for high-expressing CD38 cells • High density expression found in: • Multiple myeloma • Other B cell malignancies • Activated T cells • T cell malignancies › Late stage IND-enabling studies o IND filing: 1Q18 › Multiple Myeloma is lead indication o First-patient-in: 1H18 12 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
13.
Anti-Myeloma Activity of
CD38 CAR-T Cells In Mouse Model › On Day -23, immunodeficient NSG mice were infused with human RPMI8226 MM tumor cells › On Day 0, CAR-T cells were administered i.v. › Re-dosing was performed every 3 weeks (total of 3 CAR-T doses) Anti-CD38 CAR-T Cells Eradicated CD38 Positive Human Multiple Myeloma in NSG Mice 13 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
14.
CRITICAL ASSET =
“CAR-T” cGMP Manufacturing Capabilities (2 Sites) Providence San Diego WestCoast EastCoast Expected capacity: > 300 patients per year 14 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
15.
CRITICAL ASSET =
“Industry Leading MM Expert” Clinical Development Team › Track record of success › Led development of MM drugs o IMIDs (more than $8B in revenue) • Thalomid® (Thalidomide) • Revlimid® (Lenalidomide) • Pomalyst® (Pomalidomide) Name Position(s) Jerome B. Zeldis, M.D., Ph.D. Chief Medical Officer & President of Clinical Development Ken Takeshita, MD Sr VP Clinical Research Robert Knight, MD Sr VP Clinical Research Mark Brunswick, Ph.D. VP Regulatory Affairs and Quality Stephen L Klincewicz, DO, MPH, JD VP Pharmacovigilance and Clinical Operations 15 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
16.
SRNE Next-Generation CAR-T
Therapies What’s Next? 16 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
17.
Future Direction for
CAR-T & CAR-NK Therapies o “Viral-Free” CAR Expression o “Off-the-Shelf” (allogeneic) o Solid Tumor: o Local Infusion o “Combo” with Other Modalities 17 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
18.
Next-Generation SRNE CAR-T
Therapies: potentially faster, cheaper and easier to make! Current Limitation Next-generation Solutions Viral vector-based transduction Non-viral genetic modification Time to manufacture and release virus cGMP material Faster preclinical development Faster cGMP manufacturing steps (time & cost savings) Autologous (patient-derived) cells Allogeneic (“off-the-shelf”) donor cells Weeks until therapy manufactured Not all patients qualify for autologous approach Manufacturing costs (GMP per patient) Available to patients immediately Scalable manufacturing (many doses) Focus on hematological malignancies Combination therapy to treat solid tumors Cleaner target (lineage-restricted antigens) Easier access of CAR-T cells to tumor cells Fewer immunosuppressive effects from tumor microenvironment (TME) Loco-regional administration of CAR-T cells to avoid systemic exposure Synergy from combination therapy (immuno-oncology mAb, oncolytic virus) Genetically-engineered T cells resistant to immunosuppression 1818 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
19.
Sorrento KOKI™ CAR-T Technology Non-Viral KOKI
CAR-T Technology 19 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved * KOKI = “Knock-Out/Knock-In” non-viral technology proprietary to Sorrento therapeutics for non viral CAR-T manufacturing
20.
Non-Viral KOKI CD38-CAR-T
Cells are Functionally Similar to retrovirally-transduced CD38-CAR-T Cells 20 Donor A (#1) Cytokine analysis: 24 hours co-cultured with K562 or RPMI8226 Donor A (#1) Cytotoxicity: 3 days co-cultured with K562 and RPMI8226 0 500 1000 1500 2000 2500 3000 3500 4000 4500 pg/mL K562 RPMI8226 Cytokine Release (Interferon-γ) 0 20 40 60 80 100 Cytotoxicity(%) E:T ratio 600bp HA knockin CART RV CART TCR KO ATCKOKI CART Target Specific Cytotoxicity Donor CAR expression (KOKI) CAR expression (RV) A (exp. #1) 57% 78% A (exp. #2) 80% 71% B 72% 48% © 2018 Sorrento Therapeutics, Inc. All Rights Reserved CAR Expression
21.
Day 0 Week 1 Week
2 Week 3 Untreated Activated T RV CAR-T TCR KO-T KOKI CAR-T Anti-Tumor Activity of non-viral KOKI CD38 CAR-T Cells in RPMI8226 Model (ongoing) 21 Week 4 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
22.
Non-Viral KOKI CAR-T
Technology (Summary) › Genetic modification o results in up to 40-80% CAR-positive T cells (comparable to RV transduction) o Knock-out of TCR › Proof-of-concept for 2 different CARs o anti-CD38 o anti-CD19 › In vitro activity comparable RV-transduced CAR-T › In vivo evaluation is ongoing › IND filing planned for 2H 2018 22 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
23.
Sorrento CD38 CAR-T “CBA” (Cord
Blood Allogeneic) Off-the-Shelf CD38 CAR-T Program – “CBA” (Cord Blood Allogeneic) 23 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
24.
-T Eradication of CD38+
Human Multiple Myeloma in NSG Mice by Anti-CD38 CAR-T CBA Cells › CAR-T cells were successfully generated from Cord Blood. › CB-CAR-T cells produced less cytokines than PB-CAR-T cells when activated by targeted antigen. o Potentially lower risk of severe cytokine release syndrome (CRS). › CB-CAR-T cells exhibited similar specific anti-tumor cytotoxicity as PB-CAR-T in vitro. › CB-CAR-T cells demonstrated anti-tumor activity against MM tumor cells in an animal model. Our results indicate that anti-CD38 CB-CAR-T cells exhibit strong CD38-specific anti-MM tumor activity in vitro and in vivo. 24 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
25.
Allogeneic Cell Therapies
– Sorrento’s Strategic Partner: Celularity › Utilizes cells derived from cord blood or placental tissue o Celularity raised $250M in funding; Sorrento holds 25% equity stake o assets contributed by Sorrento, Celgene Corporation (CELG), United Therapeutics (UTHR) and Human Longevity, Inc. o only company with an allogeneic placental cell platform o placental stem cells are uniquely immune privileged not requiring cells to be engineered or matched for each individual patient. o placental stem cells allow for unprecedented scalability of Celularity's CAR-T and CAR-NK platforms 2525 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
26.
CEA CAR-T for Liver
Metastases Loco-Regional CAR-T Cell Infusion for Solid Tumors 26 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
27.
HITM Phase 1:
Patient 5 Clinical Summary BL Post-Infusion Pre-enrollment history ›Liver-only metastatic colon cancer ›Failed 3 lines of conventional chemotherapy and ablation On study events ›No detectable serum CEA; expression confirmed on tumor biopsy specimens ›Grade 1 fever and grade 3 emesis ›Liver metastasis metabolic response on PET ›No extrahepatic disease developed Follow-up ›Excellent post-study quality of life ›51 month survival 27 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
28.
HITM-SURE Phase 1b
(initial first 3 patient data) “One subject with stage IV pancreas cancer has no viable liver metastases by PET scan 11 months after treatment” 28 Press Release 03/05/18
29.
CAR-T + Oncolytic Virus Combination Therapies 29 ©
2018 Sorrento Therapeutics, Inc. All Rights Reserved
30.
and Oncolytic Viruses: Potential
Synergy with Cell-Based Immuno-Therapeutics 30 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
31.
SEPREHVIR: Leading Next-Generation
HSV-1 based Oncolytic Virus Immunotherapy TRL UL IRL IRS TRSUS Deleted ICP34.5 Deleted ICP34.5 Seprehvir (HSV1716) is a Phase II-ready HSV-1 based immuno- oncolytic therapy with over 100 patients treated to date Designed with the ability to specifically target and destroy tumor cells while also stimulating an anti-tumor T-cell mediated immune response 5 Phase I Trials: High Grade Glioma, SCCHN, melanoma, mesothelioma, pediatric neuroblastoma/osteosarcoma Well tolerated, no toxicity and expected AEs have been mild and transient Ability to be delivered intratumorally and systemically could provide administration advantages versus recently approved HSV-1 oncolytic viral immunotherapy, IMLYGIC™ (Amgen) Phase II trial in planning phase 31 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
32.
Leading Players in
the CAR-T Space $9 B (01/22/18) $11.8 B (2017) JUNO CD19 CAR-T KITE CD38 CAR-T $0.6 B (03/08/18) SRNE BCMA CAR-T $11.3 B (03/08/18) BLUE 32 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
33.
Timetable and Upcoming
Milestones › CD38 CAR-T o 1Q18 = IND filing o 1H18 = Phase 1 and First-in-Human › CD38 ADC o 2H18 = IND filing › RTX (resiniferatoxin) o 1H18 Phase 1 intractable cancer pain (epidural) first patient treated o 1Q18 IND filing (Phase 1) for osteoarthritis pain (intra-articular) + 2Q18 (First in Human) for osteoarthritis pain (intra-articular) › ZTlido™ (lidocaine topical system 1.8%) o 2019 European approval 33 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved Lead Development Programs IND Phase 1 Phase 2 Phase 3 NDA submission CD38 CAR-T (Multiple Myeloma) 1H18 CD38 ADC (Multiple Myeloma) 2H18 RTX (resiniferatoxin) - intractable pain (terminal cancer) 1H18 RTX (resiniferatoxin) - articular pain (osteoarthritis) 1H18
34.
Sorrento’s Senior Leadership
Team Name Position(s) Henry Ji, Ph.D. Chairman & CEO George Ng, J.D. EVP, Chief Administrative Officer & Chief Legal Officer Dean Ferrigno VP Finance and Chief Accounting Officer Alexis Nahama, DVM VP Corporate Development and President Ark Animal Health Hui Li, PhD VP Business Development and General Manager China Operations Bill Farley VP Business Development, Corp Dev Name Position(s) Jerome B. Zeldis, M.D., Ph.D. Chief Medical Officer & President of Clinical Development Mark Brunswick, Ph.D. VP Regulatory Affairs and Quality Robert Knight, MD Sr VP Clinical Research Ken Takeshita, MD Sr VP Clinical Research Stephen L Klincewicz, DO, MPH, JD VP Pharmacovigilance and Clinical Operations Gunnar F. Kaufmann, Ph.D. Sr VP of Immunotherapy, Head of Research and Global Partnerships 34 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
35.
(858) 203-4100 investors@sorrentotherapeutics.com 4955 Directors
Place, San Diego, CA 92121 35 © 2018 Sorrento Therapeutics, Inc. All Rights Reserved
Jetzt herunterladen